Professor Anna Norhammar
Karolinska Institute, Stockholm (Sweden)
Membership:
FESC Member
Follow
Biography
Cardiologist in Sweden with reserach in diabetes, prediabetes and cardiovascular complications as well as in lifestyle and oral health. Also concerned about how diabetes and prediabetes affects cardiovascular health in women. Experiences from RCT, registries, R-RCT and case- control studies.(DIGAMI, GAMI, Parokrank, SMARTEST, MIMET, Swedeheart). Professor of Cardiology at Karolinska Institutet. Experienced in echocardiography and non-invasiva diagnostics. Member of the Swedish Society of Cardiology steering group, and president 2024-2026.
Contributor content
Presentation
Presentation
Presentation
Heart failure and death in new users of SGLT2 inhibitors vs other glucose-lowering drugs - consistent risk reduction across patient groups in 4 countries and >270,000 patients: The CVD-REAL Study
Presentation
Dapagliflozin is associated with lower risk of hospitalization for heart failure, major adverse cardiovascular events and all-cause death compared to DPP-4i in T2D patients: CVD-REAL Nordic
Presentation
